2012 - Europe Direct Iasi

EUROINVENT 2012
anesthesia, is injected by corneal paracentesis 0.1 ml of 2.5%
avastin, after that in the conjunctival sac is instilled an antibiotic
and applied a sterile dressing for a day; after 1-4 days is carried
out a fistulising operation. The problem solved by this invention
is the prevention of the bleedings during the performance of
operations and in the postoperative period.
4.45
Title EN Method of prognosis of the evolution of endogenous uveitis
Authors Cuşnir Valeriu, Rusu Aurel, Cuşnir Vitalie
Institution State Medical and Pharmaceutical University „N. Testemitanu”
Patent no. 7001 MD
Description
EN
Method of prognosis of the evolution of uveitis endogenous,
which consists of the following: in the 3-4 day of the treatment
is collected blood, from which is separated serum by
centrifugation , determine the total number of T lymphocytes
(CD3 +) and the number of T lymphocytes mature (CD5 +), then
the index of activity (IA) is calculated and if determined values
up to 50% is predicted a favorable outcome of uveitis
endogenous and when determining values greater than 60% is
projected to unfavorable developments.
4.46
Title EN Antiinflammatory remedy in the hemorrhagic shock
Authors Vişnevschi Anatolie, Ghicavii Victor, Lutan Vasile
Institution State Medical and Pharmaceutical University „N. Testemitanu”
Patent no. 4004 MD
Description
EN
The novelty consists in the use of diethylphosphate-Sethylisothiurea
as anti-inflammatory remedy in the hemorrhagic
shock, both in pre-hospital phase and at the hospital. The results
obtained show that diethylphosphate-S-ethylisothiurea decreases
inflammatory response in the hemorrhagic shock, especially by
inhibiting iNOS, contributing to the reduction of nitrogen
monoxide (NO). The advantage consists in that use of the
product diethylphosphate-S-ethylisothiurea diminishes
inflammatory events in the human body organs and tissues in a
state of hemorrhagic shock.
Class 4
95